Vey, Norbert

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

Prébet, T., Gore, S. D., Esterni, B., Gardin, C., Itzykson, R., Thepot, S., Dreyfus, F., Rauzy, O. B., Recher, C., Adès, L., et al. (2011) · Journal of Clinical Oncology

Acute Myeloid Leukemia ResearchHematopoietic Stem Cell Transplantation

Cited by 475

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias

Rocquain, J., Carbuccia, N., Trouplin, V., Raynaud, S., Murati, A., Nezri, M., Tadrist, Z., Olschwang, S., Vey, N., Birnbaum, D., et al. (2010) · BMC Cancer

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 171

The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome

Prebet, T., Lhoumeau, A.-C., Arnoulet, C., Aulas, A., Marchetto, S., Audebert, S., Puppo, F., Chabannon, C., Sainty, D., Santoni, M.-J., et al. (2010) · Blood

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 102

Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

Reis, B., Jukofsky, L., Chen, G., Martinelli, G., Zhong, H., So, W. V., Dickinson, M. J., Drummond, M., Assouline, S., Hashemyan, M., et al. (2016) · Haematologica

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 91

The Safety and Activity of BMS‐906024, a Gamma Secretase Inhibitor (GSI) with Anti‐Notch Activity, in Patients with Relapsed T‐Cell Acute Lymphoblastic Leukemia (T‐ALL): Initial Results of a Phase 1 Trial

Zweidler-McKay, P. A., DeAngelo, D. J., Douer, D., Dombret, H., Ottmann, O. G., Vey, N., Thomas, D. A., Zhu, L., Huang, F., Bajaj, G., et al. (2014) · Blood

Acute Lymphoblastic Leukemia researchCAR-T cell therapy research

Cited by 46

A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML:GFM's “pick a winner” trial, with the impact of somatic mutations

Adès, L., Duployez, N., Guerci‐Bresler, A., Laribi, K., Peterlin, P., Vey, N., Thepot, S., Wickenhauser, S., Zerazhi, H., Stamatoullas, A., et al. (2022) · British Journal of Haematology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 21